Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Jacobsson

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
Lakartidningen|July 8, 2009
[The zero vision for suicide breaks the taboo]Danuta Wasserman, Jan Beskow, Lars Jacobsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2009
Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I studyHåkan Andersson, Elin Cederkrantz, Tom Bäck, et al.
International Journal of Radiation Oncology, Biology, Physics|October 14, 2015
Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer PatientsElin Cederkrantz, Håkan Andersson, Peter Bernhardt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 27, 2019
Intraperitoneal α-Emitting Radioimmunotherapy with <sup>211</sup>At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose EstimationsAndreas Hallqvist, Karin Bergmark, Tom Bäck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 3, 2006
Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed doseJörgen Elgqvist, Håkan Andersson, Tom Bäck, et al.
International Journal of Radiation Oncology, Biology, Physics|December 6, 2006
Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2Jörgen Elgqvist, Håkan Andersson, Peter Bernhardt, et al.
Plos One|May 14, 2015
Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200Sture Lindegren, Luciana N S Andrade, Tom Bäck, et al.
International Journal of Geriatric Psychiatry|August 2, 2003
Reducing stigma and discrimination against older people with mental disorders: a technical consensus statementNori Graham, James Lindesay, Cornelius Katona, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Lakartidningen|July 8, 2009
[The zero vision for suicide breaks the taboo]Danuta Wasserman, Jan Beskow, Lars Jacobsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2009
Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I studyHåkan Andersson, Elin Cederkrantz, Tom Bäck, et al.
International Journal of Radiation Oncology, Biology, Physics|October 14, 2015
Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer PatientsElin Cederkrantz, Håkan Andersson, Peter Bernhardt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 27, 2019
Intraperitoneal α-Emitting Radioimmunotherapy with <sup>211</sup>At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose EstimationsAndreas Hallqvist, Karin Bergmark, Tom Bäck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 3, 2006
Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed doseJörgen Elgqvist, Håkan Andersson, Tom Bäck, et al.
International Journal of Radiation Oncology, Biology, Physics|December 6, 2006
Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2Jörgen Elgqvist, Håkan Andersson, Peter Bernhardt, et al.
Plos One|May 14, 2015
Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200Sture Lindegren, Luciana N S Andrade, Tom Bäck, et al.
International Journal of Geriatric Psychiatry|August 2, 2003
Reducing stigma and discrimination against older people with mental disorders: a technical consensus statementNori Graham, James Lindesay, Cornelius Katona, et al.
Pageof 11